PENDOPHARM launches a new alcohol-free formulation of its product, PHARIXIAPrint
July 13 2020, Montreal, Quebec – With the goal of continuing to differentiate itself from the competition, and in order to increase the availability and efficiency of medication for its customers, PENDOPHARM is proud to unveil a modified version of its product, PHARIXIA, now available in an alcohol-free formula.
“Innovation plays a key role at PENDOPHARM, as is demonstrated here with an alcohol-free formulation of PHARIXIA. This product was developed to meet the demands of a vast array of patients with specific needs. I’m proud of the work the team has done, and of this accomplishment.” explained Jean-François Lemieux, Vice President and General Manager of PENDOPHARM.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately-owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 51st among Canada’s top 100 Research & Development (R&D) investors with over $43 million invested in 2018, Pharmascience Inc. is the 4th largest manufacturer of over-the-counter generic drugs in the country.
For important information please refer to the product monograph, available via https://pdf.hres.ca/dpd_pm/00054130.PDF or by calling 1-888-550-6060.
For any questions about PHARIXIA alcohol-free solution, please contact PENDOPHARM Medical Information Service by calling 1 888 550-6060 or by emailing email@example.com.